Prognostic Significance of Systemic Immune-Inflammation Index in Patients With Diffuse Large B-Cell Lymphoma

• Published in: Frontiers in oncology Vol. 11; p. 655259
• Main Authors: Wang, Zanzan, Zhang, Jiawei, Luo, Shuna, Zhao, Xiaoying
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 26.05.2021
• Subjects: diffuse large B-cell lymphoma; lymphocyte; neutrophil; Oncology; platelet; prognosis; systemic immune-inflammation index; systemic immune-inflammation index; platelet; diffuse large B-cell lymphoma; nomogram; neutrophil; prognosis; lymphocyte
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2021.655259

The systemic immune-inflammation index (SII) based on neutrophil, platelet and lymphocyte counts, is a prognostic biomarker in some solid cancers. However, the prognostic value of SII has not yet been validated. This study was to evaluate the role of SII in predicting survival for patients with diffuse large B cell lymphoma (DLBCL). We retrospectively investigated 224 patients with DLBCL between August 2005 and October 2018. Kaplan-Meier analysis and Cox proportional hazard models were used to assess the prognostic value of SII. In the ROC curve analysis, SII had the highest AUC and was more accurate as a prognostic factor. Patients with higher SII tended to have higher level of LDH, more advanced stage, poor PS, and high IPI score compared with low SII group. In univariate analyses, SII, PLR and NLR were all prognostic for progression-free survival and overall survival. Moreover, only SII, older age, HBSAg-positive and IPI were the independent prognostic factors for patients in multivariate analysis. The nomogram based on SII, older age, HBSAg status and IPI showed accurate prognostic ability for predicting 3-years and 5-years survival rates (c-index, 0.791) compared to the IPI alone (c-index, 0.716). SII was a powerful tool for predicting outcome in patients with DLBCL. It might assist the separation of high-risk patients among patients with the same IPI.